The estimated Net Worth of Robert J Alpern is at least $17.4 Million dollars as of 21 November 2022. Robert Alpern owns over 27,584 units of Abbott Laboratories stock worth over $15,377,091 and over the last 16 years he sold ABT stock worth over $1,634,108. In addition, he makes $390,233 as Independent Director at Abbott Laboratories.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Alpern ABT stock SEC Form 4 insiders trading
Robert has made over 14 trades of the Abbott Laboratories stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 131,879 units of ABT stock worth $27,695 on 23 November 2022.
The largest trade he's ever made was selling 131,879 units of Abbott Laboratories stock on 23 November 2022 worth over $27,695. On average, Robert trades about 1,264 units every 8 days since 2008. As of 21 November 2022 he still owns at least 131,879 units of Abbott Laboratories stock.
You can see the complete history of Robert Alpern stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Alpern biography
Dr. Robert J. Alpern, M.D. , serves as Independent Director of the Company. Dr. Alpern has served as the Ensign Professor of Medicine and Professor of Internal Medicine at Yale School of Medicine since June 2004. From June 2004 to January 2020, Dr. Alpern served as Dean of Yale School of Medicine. From July 1998 to May 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical Center. Dr. Alpern also serves as a Director of AbbVie Inc. and Tricida, Inc. and served as a Director on the Board of Yale New Haven Hospital from October 2005 through January 2020. As a result of his long-tenured leadership positions at the Yale School of Medicine and The University of Texas Southwestern Medical Center, and as a former Director on the Board of Yale New Haven Hospital, Dr. Alpern contributes valuable insights to the Board through his medical and scientific expertise and his knowledge of the health care environment and the scientific nature of Abbott's key research and development initiatives.
What is the salary of Robert Alpern?
As the Independent Director of Abbott Laboratories, the total compensation of Robert Alpern at Abbott Laboratories is $390,233. There are 12 executives at Abbott Laboratories getting paid more, with Miles White having the highest compensation of $27,802,800.
How old is Robert Alpern?
Robert Alpern is 69, he's been the Independent Director of Abbott Laboratories since 2008. There are 4 older and 39 younger executives at Abbott Laboratories. The oldest executive at Abbott Laboratories is Samuel Scott, 75, who is the Independent Director.
What's Robert Alpern's mailing address?
Robert's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.
Insiders trading at Abbott Laboratories
Over the last 24 years, insiders at Abbott Laboratories have traded over $388,257,551 worth of Abbott Laboratories stock and bought 1,028,477 units worth $44,923,618 . The most active insiders traders include Miles D White, Richard A Gonzalez und Jeffrey M Leiden. On average, Abbott Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,003,344. The most recent stock trade was executed by John A. Jr. Mccoy on 1 September 2024, trading 27 units of ABT stock currently worth $3,100.
What does Abbott Laboratories do?
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.
What does Abbott Laboratories's logo look like?
Complete history of Robert Alpern stock trades at Abbott Laboratories, Abbvie Inc und Tricida Inc
Abbott Laboratories executives and stock owners
Abbott Laboratories executives and other stock owners filed with the SEC include:
-
Miles White,
Executive Chairman of the Board -
Robert Ford,
President, Chief Executive Officer, Director -
Lisa Earnhardt,
Executive Vice President - Medical Devices -
Hubert Allen,
Executive Vice President, General Counsel, Secretary -
Miles D. White M.B.A.,
Exec. Chairman -
Daniel Salvadori,
Executive Vice President - Nutritional Products -
Robert B. Ford,
Chairman, Pres & CEO -
John Capek,
Executive Vice President - Ventures -
Robert E. Funck Jr.,
Exec. VP of Fin. & CFO -
Hubert L. Allen,
Exec. VP, Gen. Counsel & Sec. -
Daniel Gesua Sive Salvadori,
Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products -
John F. Ginascol,
Exec. VP of Core Diagnostics -
Robert Alpern,
Independent Director -
Sally Blount,
Independent Director -
Glenn Tilton,
Independent Director -
Samuel Scott,
Independent Director -
William Osborn,
Lead Independent Director -
Roxanne Austin,
Independent Director -
Edward Liddy,
Independent Director -
Phebe Novakovic,
Independent Director -
Nancy McKinstry,
Independent Director -
Michelle Kumbier,
Independent Director -
John Stratton,
Independent Director -
Daniel Starks,
Independent Director -
Darren McDew,
Independent Director -
Randel Woodgrift,
Senior Vice President - CRM -
Alejandro Wellisch,
Senior Vice President - Established Pharmaceuticals, Latin America -
Jared Watkin,
Senior Vice President - Diabetes Care -
Christopher Scoggins,
Senior Vice President - Rapid Diagnostics -
Michael Pederson,
Senior Vice President - Electrophysiology and Heart Failure -
Joseph Manning,
Senior Vice President - Nutrition International -
Sammy Karam,
Senior Vice President - Established Pharmaceuticals, Emerging Markets -
Michael Dale,
Senior Vice President - Structural Heart -
Jaime Contreras,
Senior Vice President - Core Laboratory Diagnostics, Commercial Operations -
Charles Brynelsen,
Senior Vice President - Abbott Vascular -
Roger Bird,
Senior Vice President - U.S. Nutrition -
Andrea Wainer,
Executive Vice President - Rapid and Molecular Diagnostics -
Andrew Lane,
Executive Vice President - Established Pharmaceuticals -
John Ginascol,
Executive Vice President - Core Diagnostics -
Mary Moreland,
Executive Vice President of Human Resources -
Robert Funck,
Chief Financial Officer, Executive Vice President - Finance -
Gregory A. Ahlberg,
Sr. VP of Core Laboratory Diagnostics & Commercial Operations -
Elaine R. Leavenworth,
Sr. VP and Chief Marketing & External Affairs Officer -
Melissa Brotz,
VP of Public Affairs & Corp. Marketing -
James E. Young,
VP and Chief Ethics & Compliance Officer -
Scott Michael Leinenweber,
VP of Investor Relations, Licensing & Acquisitions -
Sean Shrimpton,
Senior Vice President -
Deepak S. Nath,
Senior Vice President -
Brian B Yoor,
Executive Vice President & CFO -
Brian J Blaser,
Senior Vice President -
Stephen R Fussell,
Senior Vice President -
Michael J Warmuth,
Senior Vice President -
Eric S Fain,
Senior Vice President -
Sharon J Bracken,
Senior Vice President -
Michael T Rousseau,
Pres., Cardiovasc. & Neuromod. -
Richard W Ashley,
Executive Vice President -
Christopher J. Calamari,
SENIOR VICE PRESIDENT -
Julie L. Tyler,
SENIOR VICE PRESIDENT -
Jean Yves Pavee,
Senior Vice President -
W James Farrell,
Director -
Thomas C Freyman,
Senior Vice President -
Georges H. De Vos,
Senior Vice President -
Katherine C. Doyle,
Senior Vice President -
J. Scott White,
Senior Vice President -
Charles D Foltz,
Senior Vice President -
Murthy V Simhambhatla,
Senior Vice President -
Thomas G Frinzi,
Senior Vice President -
John C Landgraf,
Senior Vice President -
Greg W Linder,
Vice President -
Heather L Mason,
Senior Vice President -
Paul K Magill,
Senior Vice President -
A. David Forrest,
Senior Vice President -
H Laurance Fuller,
Director -
Carlos Alban,
Senior Vice President -
James V Mazzo,
Senior Vice President -
Holger A Liepmann,
Senior Vice President -
William D Smithburg,
Director -
Laura J Schumacher,
Senior Vice President -
David Owen,
Director -
Edward L. Michael,
Senior Vice President -
Richard A Gonzalez,
Chief Operating Officer -
Donald V Jr Patton,
Senior Vice President -
William M Daley,
Director -
Robert B Hance,
Senior Vice President -
Mary T Szela,
Senior Vice President -
Roy S Roberts,
Director -
Corlis D Murray,
Senior Vice President -
Thomas F Chen,
Senior Vice President -
Olivier Bohuon,
Senior Vice President -
James L Tyree,
Senior Vice President -
W Ann Reynolds,
Director -
Boone Jr Powell,
Director -
Edward J Fiorentino,
Senior Vice President -
Gary E Mccullough,
Senior Vice President -
Jeffrey M Leiden,
President & COO -
Jack M Greenberg,
Director -
Joseph M Nemmers,
Senior Vice President -
John R Walter,
Director -
Jeffrey R Binder,
Senior Vice President -
William G Dempsey,
Senior Vice President -
A Barry Rand,
Director -
Thomas M Wascoe,
Senior Vice President -
Christopher B Begley,
Senior Vice President -
Lance B Wyatt,
Senior Vice President -
Guillermo A Herrera,
Senior Vice President -
Lasa Jose M De,
Senior Vice President -
Fernando Mateus,
SENIOR VICE PRESIDENT -
Gregory A Ahlberg,
SENIOR VICE PRESIDENT -
John A. Jr. Mccoy,
VICE PRESIDENT -
Philip P Boudreau,
EXECUTIVE VICE PRESIDENT -
Claire Babineaux Fontenot,
-
Michael O'grady,
-
Louis H. Morrone,
EXECUTIVE VICE PRESIDENT -
Patricia Paola Gonzalez,
-
Michael F Roman,